RESEARCH MONOGRAPH · KDC-MN-185

SAM-e (S-Adenosyl-L-Methionine)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

70/100

The universal methyl donor, real depression and joint signal, and stability is the biggest practical problem

SAM-e (S-adenosyl-L-methionine) is the principal biological methyl donor and one of the most metabolically important small molecules in the body. It's produced from methionine and ATP via methionine adenosyltransferase, donates methyl groups to a large fraction of cellular methylation reactions (DNA, histones, phospholipids, neurotransmitters, creatine, carnitine), and gets recycled through the methionine cycle via S-adenosyl-homocysteine and homocysteine back to methionine.

The supplemental story has been driven by depression and osteoarthritis evidence, and that evidence is actually fairly substantial. SAM-e at 800-1600mg daily has been compared head-to-head against tricyclics and SSRIs in multiple trials, with comparable response rates and faster onset in some studies. The 2020 Cochrane review pulled positive depression conclusions with caveats about study quality. The osteoarthritis literature is similarly real, with effect sizes comparable to NSAIDs for pain and function at 1200mg daily across multiple trials.

Mechanism for the mood effects is multi-target. Direct methylation of neurotransmitter synthesis pathways (catecholamine production via COMT-related steps, indolamine pathways), phosphatidylcholine production affecting membrane fluidity, and modulation of methylation balance via the SAM/SAH ratio. Genetic methylation variants (MTHFR C677T particularly) modulate response and are an interesting research angle. For joint effects the mechanism is partly cartilage matrix synthesis support via methylation of proteoglycan precursors.

The stability problem is the practical headache. SAM-e is genuinely unstable as the free molecule, decomposes readily, and the salt forms (tosylate disulfate, butanedisulfonate are the most common) are necessary for any kind of shelf life. Even with salt formulation, enteric coating is required for any meaningful oral bioavailability, and a lot of consumer-grade SAM-e on the market degrades fast enough that label claims dont match actual deliverable SAM-e at end of shelf life. This is one of the worst stability-and-QC problems in the supplement industry.

Sourcing matters more than for almost anything else here. Reputable enteric-coated stabilized formulations from major manufacturers (Nature Made, Doctor's Best, Jarrow) are usable. Bulk SAM-e powder is essentially garbage because it degrades before you can use it.

Safety is generally clean at supplemental doses. Theoretical concerns about driving manic episodes in bipolar disorder are worth noting.

What we like: real human evidence in depression and OA, important biology. What we dont like: the stability nightmare means most product on the market is far below label claim by purchase time.

Evidence: 75
Mechanism: 85
Reliability: 65
Safety: 75
Sourcing: 55
Value: 55
Signal: 75
Staying power: 78

Plain-language summary Intrigue 65 / 100

SAM-e is the body's principal methyl donor, used in countless biological reactions including neurotransmitter synthesis. As a supplement it has antidepressant effects with reasonable evidence and is used for liver disease and osteoarthritis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous methyl donor

S-adenosyl-L-methionine, the principal methyl donor for cellular methylation reactions, supplemented for depression, osteoarthritis, and liver disease.

Abstract

SAM-e (S-adenosyl-L-methionine; CAS 29908-03-0; molecular formula C15H22N6O5S; molecular weight 398.44) is an endogenous nucleotide-amino acid conjugate that serves as the principal methyl donor for hundreds of cellular methylation reactions, including DNA methylation, neurotransmitter synthesis, phospholipid synthesis, and detoxification. Synthesis from methionine + ATP is rate-limited; supplementation provides methyl donor capacity. The compound is approved as a medicine in some European countries for depression and osteoarthritis; sold as a dietary supplement in the United States. Clinical evidence in depression is moderate (effect sizes comparable to standard antidepressants in small trials). Reported research dose ranges in the literature are described in the source publications. Can precipitate mania in bipolar patients; should not be combined with MAOIs.

Mechanism of action

Principal cellular methyl donor; substrate for many methyltransferase reactions.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Papakostas GI, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders. Am J Psychiatry 2010.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-185

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

SAM-e (S-Adenosyl-L-Methionine)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs